CYP2B6 Q172H - GET-Evidence

Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.

To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.

Please help improve GET-Evidence by evaluating evidence for this variant!


(See the latest version)

CYP2B6 Q172H

(CYP2B6 Gln172His)

You are viewing an old version of this page that was saved on December 27, 2009 at 4:09pm by Genome Importing Robot.

Short summary


Variant evidence
Computational -
Functional -
Case/Control -
Familial -
Clinical importance
Severity -
Treatability -
Penetrance -


Insufficiently evaluated not reviewed

(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)

Inheritance pattern


Summary of published research, and additional commentary


Allele frequency

  • T @ chr19:41512841: 29.2% (3138/10758) in EVS
  • T @ chr19:46204680: 31.2% (40/128) in GET-Evidence
  • Frequency shown in summary reports: 29.2% (3138/10758)



Added in this revision:







Other external references

  • [HIV Infections]
    This variant in exon 4 together with K262R in exon 5 are the determining SNP of the *6 allele. *6 occurs with high frequency across different populations. A study in human liver microsomes found the CYP2B6*6 allele was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. In a study in HIV-1 patients treated with efavirenz, the mean plasma efavirenz concentration of patients with CYP2B6 *6/*6 was significantly higher than that of patients with genotypes *6 heterozygote or without alleles *6. In vitro expression studies found the 516G>T variant as the causal sequence variation for severely decreased expression and function associated with CYP2B6*6.; PubMed ID:17559344; PubMed ID:17638512; PubM
  • [efavirenz; nevirapine]
    CYP2B6:516G>T is part of the CYP2B6 haplotype. It has been associated with lower activity and response to NNRTIs. See VIP annotation for more details.
  • [Drug Toxicity]
    Risk or phenotype-associated allele: T. Phenotype: CYP2B6*6 genotype of the transplant donor was associated with toxicity and venoocclusive disease of the liver in the recipient. Study size:107 . Study population/ethnicity: Donors and patients with leukemia after HLA-identical hematopoietic stem cell transplantation, France. Significance metric(s): p = 0.03. Type of association: TOX
  • Score: 0.009 (benign)

Other in silico analyses

  • NBLOSUM100 score = –1
  • GET-Evidence autoscore = 1

Edit history

Gene search

"GENE" or "GENE A123C":

Log in